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Abstract
We present herein our 20-year experience of pubertal induction in apubertal older 
(median age 56 years; range 38.4–69.5) men with congenital hypogonadotrophic 
hypogonadism (n = 7) using a simple fixed-dose and fixed-interval intramuscular 
testosterone that we originally pioneered in relation to achieving virilisation of natal 
female transgender men. This regime was effective and well tolerated, resulting 
in complete virilisation by around 1 year after treatment initiation. No physical or 
psychological adverse effects were encountered in this group of potentially vulnerable 
individuals. There were no abnormal excursions of laboratory parameters and extended 
follow-up beyond the first year of treatment revealed remarkable improvements in 
bone density. We highlight advantages to both patients and physicians of this regime 
in testosterone-naïve older men with congenital hypogonadism and discourage the 
over-rigid application to such patients of treatment algorithms derived from paediatric 
practice in relation to the evaluation and management in younger teenagers with 
delayed puberty of uncertain cause.
Introduction
Delayed puberty is defined by the absence of testicular 
development 2.5 s.d. later than the population mean – 
typically 14 years of age in males (1). Although the majority 
of cases at age 14 have constitutional delay (CDP), the 
proportion of males with congenital hypogonadotrophic 
hypogonadism (CHH) rises steeply thereafter, eventually 
comprising the universality of cases by the third decade 
of life (2). Whereas both primary and secondary (CHH) 
ovarian insufficiencies can present with absent puberty 
in females, male hypogonadism in the context of absent 
puberty is almost invariably secondary (CHH) (1).
Although sharing a common clinical presentation 
and biochemistry with CDP, most CHH cases should be 
identifiable at baseline evaluation due to the presence of one 
or more red flags (e.g. congenital non-reproductive defects, 
particularly anosmia; history of testicular maldescent or 
neonatal micropenis, indicating likely absent minipuberty) 
(3), with the remainder being identifiable later during the 
process of pubertal induction through failure to normalise 
testicular volume with testosterone therapy (1).
Given the aforementioned factors, the diagnostic 
evaluation and management of pubertal delay should 
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be completed during the adolescent years, and yet this 
remains patently not the case. In line with the shared 
experiences of CHH men posted on online forums, two 
large CHH studies (one a traditional UK case notes-based 
series and another an international online patient survey), 
whose data collection was separated by over 20  years, 
found the median age of initiation of any meaningful 
treatment to be 18–19  years (4, 5). The predominant 
reasons for treatment delay emerging from these studies 
are listed in Table  1, with almost all these coming into 
play for certain unfortunate individuals (6). In practice, 
the significance of CHH red flags is usually missed, both 
perinatally and in adolescence, leading to unnecessary 
delays in diagnosis and treatment (3).
CHH men with absent (around two-thirds of the cases) 
or arrested partial puberty (one-third) can thus present via 
a variety of routes in later life, e.g. during investigation 
of anaemia, muscle weakness, osteoporosis, infertility or 
sexual dysfunction, as a result of patients having finally 
summoned the courage to seek medical attention, or just 
serendipitously. Physicians facing an older man exhibiting 
congenital absence of puberty – possibly for the first time 
in their careers – notably lack published guidance on how 
best to initiate treatment (which product, how much and 
how quickly?). They understandably turn for guidance to 
their paediatrician colleagues, who encounter disorders of 
puberty far more commonly.
Paediatric practice and guidance are universally 
based upon the ‘delayed puberty – query cause’ (DPQC) 
pathway, which understandably emphasises the 
importance of reassurance and the avoidance of over-
medicalisation, recommending low-dose, low-frequency 
pulses of testosterone if/when treatment is required  (7). 
For adolescent boys, in whom delay is usually 
constitutional, testosterone treatment is typically initiated 
as low-dose intramuscular (IM) pulses, with the dose and/
or frequency tailored to allow clinical (testicular volume) 
and biochemical windows of opportunity for identifying 
endogenous gonadotrophin secretion. In teenagers with 
CHH or other organic hypogonadism, the aims are to 
recapitulate the normal tempo of male puberty over 
2–3 years, whilst optimising linear growth potential and 
not masking evidence for endogenous gonadotrophin-
dependent puberty should it emerge (1).
However, for those with ‘totally obvious CHH’ 
(TOCHH – e.g. teenager with congenital anosmia or history 
of bilateral cryptorchidism, or any apubertal man in his 
third decade or beyond), feeding them into the DPQC 
pathway merely imposes unnecessary delays. Regimes 
envisaged and designed for teenagers with suspected CDP 
offer frustratingly slow progress for older CHH men, who 
have already attained near-final height, often exhibit 
segmental disproportion and, having experienced years 
of medical procrastination, express a reasonable desire 
to complete puberty without undue delay (6). Moreover, 
any opportunity for age-appropriate recapitulation of the 
normal tempo of puberty is long past.
Overvalued concerns that testosterone therapy 
might precipitate acute behaviour change – aggression, 
hypersexuality or priapism – in older apubertal men are 
surprisingly common among physicians, potentially 
further contributing to excessive caution with testosterone 
dosing in older men. Moreover, older men are more likely 
to harbour non-gonadal comorbidities for which there also 
seem to be lingering physician misconceptions in relation 
to the ‘risks’ of testosterone initiation. In addition, older 
men lacking capacity may no longer have a living relative 
for discussions of best interests. That CHH which is itself 
frequently associated with profound psychosocial issues 
adds another layer of complexity (8). Nevertheless, expert 
guidance is unequivocal, stating that age or disability per se 
should not constitute barriers to initiation of testosterone 
therapy in CHH (9).
The rarity of CHH (around 1 in 4000 males) (10) limits 
the accrual of experience even in the most specialist centres 
such as our own. The questions remain: what should the 
TOCHH pathway look like for a testosterone-naïve older 
man? And are there useful, and potentially more appropriate, 
experiences to be drawn from medical specialties other 
than paediatrics? Herein, we present our experience of a 
Table 1 Factors underlying delayed initiation of age-appropriate treatment for CHH males.
Patient/parent factors Delayed presentation
Failure to attend follow-up visits
Failure to adhere to prescribed treatment
Physician factors/errors 
 
 
 
 
Belief that ‘simple reassurance’ is the only required first-line management for case of absent puberty 
beyond age 14
Belief that partial puberty (testicular volume ≥4 mL) means that progression of puberty to 
completion is inevitable, so that patients can thus be safely discharged from follow-up
Failure to identify or recognise the significance of ‘red flag’ features pointing to CHH over CDP
Failure to prescribe clinically-meaningful doses of testosterone to adult men with confirmed CHH
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simple 1-year (fixed-dose; fixed-interval) completion-of-
puberty regime with IM testosterone in older CHH men, 
presenting with untreated (or minimally treated) puberty. 
This regime has been significantly informed by our parallel 
clinical experience in achieving virilisation of testosterone-
naïve (natal female) transgender males.
Patients and methods
Case records were reviewed for all CHH men (n = 7) who 
have been undergoing pubertal induction with testosterone 
at our centre since 1998 – aged 35  years or older. The 
diagnoses comprised Kallmann’s syndrome (n = 5), 
normosmic CHH (n = 1) and CHARGE syndrome (n = 1). 
Their clinical ‘vignettes’ are detailed in supplementary data 
(see section on supplementary data given at the end of this 
article), and offer some insights into the reasons for their 
extreme delay in presentation, but it was notable that one 
had major physical and learning impairments and another 
presented with life-changing injuries resulting from major 
self-harm episode influenced by low self-esteem.
Median age at treatment initiation was 56  years 
(range 38.4–69.5). Treatment over the first year was with 
IM Sustanon 250 mg administered monthly (n = 1), or 
testosterone undecanoate 1 g (Nebido/Reandron-TU) 
administered around four months apart (n = 6) – omitting 
the usual loading dose recommended at 6  weeks. All 
patients additionally received daily supplementation with 
calcium and cholecalciferol.
The data presented in this manuscript originated 
not from a registered clinical trial, but from an internal 
audit of our established clinical practice. Therefore, formal 
institutional ethical approval was not required, because 
non-identifiable data are used with all subjects or guardians 
consenting to the inclusion of the data being presented.
Statistical analysis was performed using SPSS for 
Windows version 22 (IBM SPSS Statistics 22). Data 
presented are expressed as medians with interquartile 
ranges. Pre- and post-treatment parameters were compared 
using the Mann–Whitney U-test.
Results
Longitudinal data detailing pubertal staging, laboratory 
parameters and bone mineral density are shown in 
Table 2. All patients completed puberty within a year of 
treatment initiation. Of those who were able to express an 
opinion (n = 6) were very satisfied with the pace of change 
and final outcome, with similar views being expressed by 
the carers of patient 5. As expected for a group of men with 
CHH, rather than DPQC, none developed any features 
of endogenous puberty, such as an increase in trough 
LH concentration greater than 2.0 IU/L, or testicular 
enlargement greater than 4 mL.
During testosterone treatment, there were no adverse 
effects recorded, except for rapidly progressive male-pattern 
baldness (n = 1). Despite the presence of major cognitive 
or psychological issues in three out of seven men prior 
to initiation of testosterone therapy, there were neither 
adverse psychological events recorded nor any worsening 
in mood or behaviour noted during treatment. In the 
CHARGE patient-lacking capacity, DISDAT (Disability 
Distress Assessment Tool (http://prc.coh.org/PainNOA/
Dis%20DAT_Tool.pdf) scores regularly calculated by 
experienced disability care staff remained stable.
Trough serum testosterone concentrations during 
treatment did not show any wide excursions and, as 
expected, therapy resulted in significantly increased 
haemoglobin concentration (122 ± 29–157 ±8 g/L) and 
haematocrit (37% ± 9–45% ± 5) – (P < 0.05), but without 
any supraphysiological rise. Patient numbers were 
necessarily insufficient in respect of detecting significant 
changes in lipid profile, PSA or HbA1c, but the raw data 
appeared very reassuring. Follow-up beyond the initial 
year of treatment revealed a median increase of 49% in 
lumbar spine bone mineral density: median t-score rising 
from minus 3.5 ± 1.0 at baseline to minus 1.8 ± 1.2 after a 
median 6 years of testosterone therapy (P < 0.05).
Discussion
Aside from isolated reports and conference abstracts, this 
is the first systematic evaluation of pubertal induction 
(methods and outcomes) in testosterone-naïve older men 
with congenital hypogonadism. Subject to necessarily 
limited patient numbers accruing to a less common 
presentation of a rare disease, we have demonstrated that 
completion of puberty over 1  year with IM testosterone 
can be achieved with patients’ satisfaction and without 
significant adverse events in older apubertal men with CHH; 
thereafter, there are sustained major improvements in bone 
mineral density, even as far as the sixth and seventh decades 
of life. Pubertal induction in this context can be achieved 
using either short- or long-acting IM testosterone injections, 
but depot-TU conveniently minimises outpatient visits.
Although baseline osteopaenia or osteoporosis is 
entirely expected in these patients, as a result of congenital 
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androgen deficiency, our protocol is to defer adjuvant 
antiresorptive therapy until anabolic (testosterone-
driven) improvements in bone mineral density have 
plateaued. We would, of course, revisit this strategy in the 
event of intercurrent spinal fracture for which parenteral 
antiresorptives may also be beneficial for pain control and 
bone remodelling, but have not yet faced this scenario in 
this group of patients.
Despite widespread physician concerns about 
potential behaviour disturbance in testosterone-naïve 
adult men undergoing physiological normalisation of 
serum testosterone, literature review failed to uncover 
any evidence to underpin these concerns. This reflects 
our experience reported herein, which is in line with 
that of clinicians treating much larger numbers of older 
testosterone-naïve transgender males with cross-hormone 
regimes. Transgender men have a particularly high 
baseline prevalence of psychological/psychiatric disease 
and are likewise virilised fairly rapidly, and yet significant 
testosterone-related behaviour disturbance has not been 
observed in this population (11, 12).
However, we emphasise that the regime described 
herein delivers just 2 g of TU over the first 32  weeks of 
therapy and, in testosterone-naïve men, would strongly 
caution against using standard TU initiation regimes 
as per the product datasheet comprising two injections 
spaced 6 weeks apart followed by 12-weekly maintenance 
injections (i.e. cumulative 4 g of TE over the first 30 weeks 
of therapy).
Conclusions
We suggest that clinicians avoid reflexly applying DPQC 
management algorithms to older testosterone-naïve men 
(or younger ones with ‘red flags’ for CHH). We instead 
commend to them this simple and well-tolerated pubertal 
induction regime using fixed-dose and fixed-interval IM 
testosterone. In respect of potential psychological issues 
experienced by older testosterone-naïve men during 
pubertal induction, we believe that the more transferrable 
lessons emerge from the transgender – rather than the 
adolescent – literature.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-17-0241.
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